Authors:
Anscher, MS
Marks, LB
Shafman, TD
Clough, R
Huang, H
Tisch, A
Munley, M
Herndon, JE
Garst, J
Crawford, J
Jirtle, RL
Citation: Ms. Anscher et al., Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation, J CL ONCOL, 19(17), 2001, pp. 3758-3765
Authors:
Hernando, ML
Marks, LB
Bentel, GC
Zhou, SM
Hollis, D
Das, SK
Fan, M
Munley, MT
Shafman, TD
Anscher, MS
Lind, PA
Citation: Ml. Hernando et al., Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer, INT J RAD O, 51(3), 2001, pp. 650-659
Authors:
Shafman, TD
Levitz, S
Nixon, AJ
Gibans, LA
Nichols, KE
Bell, DW
Ishioka, C
Isselbacher, KJ
Gelman, R
Garber, J
Harris, JR
Haber, DA
Citation: Td. Shafman et al., Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor, GENE CHROM, 27(2), 2000, pp. 124-129
Authors:
Cokgor, I
Akabani, G
Kuan, CT
Friedman, HS
Friedman, AH
Coleman, RE
McLendon, RE
Bigner, SH
Zhao, XG
Garcia-Turner, AM
Pegram, CN
Wikstrand, CJ
Shafman, TD
Herndon, JE
Provenzale, JM
Zalutsky, MR
Bigner, DD
Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872